TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30433862
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg oral BH4 (BH4-5)
Study: 30433862
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg oral BH4 (BH4-20)
Study: 26438119
Drug: mDCF (fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: mDCF (fluorouracil 2,000 mg/m2 IV over 48 hours, docetaxel 40 mg/m2 IV on day 1, cisplatin 40 mg/m2 IV on day 3, every 2 weeks)
Study: 26438119
Drug: DCF (docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCF (docetaxel 75 mg/m2, cisplatin 75 mg/m2, and fluorouracil 750 mg/m2 IV over 5 days with granulocyte colony‐stimulating factor, every 3 weeks)
Study: 23039034
Drug: Lopinavir/Ritonavir (LPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/Ritonavir (LPV/r) 40/10 mg twice daily if 2-4 kg and 80/20 mg twice daily if >4 kg
Study: 23039034
Drug: Lamivudine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 7.5 mg twice daily if 2-4 kg, 25 mg twice daily if 4-8 kg and 50 mg twice daily if >8 kg
Study: 19874149
Drug: Visual impairment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visual impairment, self‐reported poor vision, dependence in daily activities, cognitive impairment, depressive symptoms, female gender, older age
Study: 17700042
Drug: S 17092
Approvals — FDA: no, EMA: no, PMDA: no
Description: S 17092 (100, 200, 400 or 600 mg)
Study: 23088748
Drug: Intravenous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous insulin therapy
Study: 23088748
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin therapy
Study: 406561
Drug: Intramuscular insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular insulin therapy
Study: 30443924
Drug: Good adherence
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Good adherence to HTN treatment
Study: 30443924
Drug: Poor adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poor adherence to HTN treatment
Study: 25821405
Drug: Remifentanil 1
Normalized name: remifentanil 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 1 μg/kg administered 30 seconds before induction
Study: 23445184
Drug: Caregiver-mediated medication
Normalized name: carbinoxamine maleate Oral Solution [Pediatex]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caregiver-mediated medication management
Study: 21388549
Drug: Enteral rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral rosuvastatin administered once daily for 14 days
Study: 21388549
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo administered once daily for 14 days
Study: 19270824
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy (CRT) with capecitabine and cisplatin
Study: 17355494
Drug: Thioctic acid
Normalized name: Thioctic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thioctic acid 600 mg p.o./day
Study: 12765890
Drug: parecoxib 40
Normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: parecoxib 40 mg i.v.
Study: 17257175
Drug: ketorolac 30
Normalized name: ketorolac 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketorolac 30 mg i.v.
Study: 26607392
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (800 μg/day for 16 weeks)
Study: 22294059
Drug: Lercanidipine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lercanidipine administered in the fasted state
Study: 22294059
Drug: Lercanidipine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lercanidipine administered 15 min before a standard breakfast
Study: 10587334
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of lisinopril (32.5 to 35 mg daily)
Study: 10587334
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of lisinopril (2.5 to 5.0 mg daily)
Study: 9193426
Drug: High ACE
Normalized name: HIGH ACETATE MULTIPLE ELECTROLYTE ADDITIVE INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: High ACE activity (> 12 IU/L)
Study: 9193426
Drug: Low ACE
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low ACE activity (<= IU/L)
Study: 1554040
Drug: Progesterone suppository
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone suppository treatment
Study: 2861874
Drug: Intramuscular pipothiazine
Normalized name: pipothiazine
DrugBank: Pipotiazine (DB01621)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular pipothiazine palmitate (PP)
Study: 24764147
Drug: Metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin + Pantoprazole
Study: 24764147
Drug: Metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin + Rabeprazole
Study: 11278152
Drug: Medicated schizophrenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicated schizophrenic patients during initial assessment after receiving medication
Study: 11278152
Drug: Medicated schizophrenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicated schizophrenic patients after sustained treatment
Study: 11278152
Drug: First-episode schizophrenic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-episode schizophrenic patients (medication-naïve or not)
Study: 30149417
Drug: Dapagliflozin 10
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 10 mg once a day for 12 weeks
Study: 30037778
Drug: Donepezil 5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 5-10 mg daily
Study: 26540028
Drug: Erlotinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (150 mg/d) for 12 months
Study: 21051191
Drug: modified Constraint‐Induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: modified Constraint‐Induced Movement Therapy followed by Bimanual Training (mCIMT‐BiT)
Study: 18484473
Drug: Carbapenem monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbapenem monotherapy (imipenem or meropenem)
Study: 17139586
Drug: Short-acting insulin
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting insulin analogs
Study: 17139586
Drug: Meta-analyses of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meta-analyses of short-acting insulin analogs
Study: 11783322
Drug: Longshoudan (LSD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longshoudan (LSD) treatment for 4 weeks
Study: 3479839
Drug: Active drug
Normalized name: Capillary active drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug period
Study: 3479839
Drug: Non-steroidal anti-inflammatory
Normalized name: Non-steroidal anti-inflammatory agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroidal anti-inflammatory drug (NSAID) or analgesic trials
Study: 31857431
Drug: Adavosertib (110
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adavosertib (110 mg/m2) with Irinotecan (90 mg/m2)
Study: 31857431
Drug: Adavosertib (85
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adavosertib (85 mg/m2) with Irinotecan (90 mg/m2)
Study: 25796155
Drug: Tongxinluo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongxinluo capsule (control)
Study: 23782950
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation (100 μg once daily for 24 to 30 months)
Study: 23782950
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with anti‐thyroid drugs
Study: 21112881
Drug: Continuous interscalene
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous interscalene ropivacaine 0.2% 2 ml h⁻¹ with mandatory 6 hourly boluses
Study: 21112881
Drug: Continuous interscalene
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous interscalene ropivacaine 0.2% 5 ml h⁻¹ with PRN boluses
Study: 15491239
Drug: Paroxetine CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine CR 12.5 mg
Study: 15491239
Drug: Paroxetine CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine CR 25 mg
Study: 14704300
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (160 mg of ferrous sulfate, 50 mg elemental iron, twice daily; total of 320 mg ferrous sulfate, 100 mg elemental iron daily)
Study: 2424341
Drug: Prophylactic corticosteroid
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic corticosteroid and/or antihistamine pretreatment
Study: 18227177
Drug: Vancomycin >=4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin >=4 g/day
Study: 18227177
Drug: Vancomycin <4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin <4 g/day
Study: 1932300
Drug: Standard IVIG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard IVIG (Sandoglobulin, 0.1 mg/kg IgM)
Study: 1932300
Drug: IgM-enriched IVIG
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgM-enriched IVIG (Pentaglobin, 30 mg/kg IgM)
Study: 19411614
Drug: Active drug
Normalized name: Capillary active drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug treatment (exact drug not specified)
Study: 15658650
Drug: Decoction of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decoction of Qingre Huoxue recipe (QHR) given one dose per day in addition to standard treatment.
Study: 15658650
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment including impact therapy of methyl-prednisolone followed by oral prednisone, with additional cyclophosphamide or mycophenolate mofetil for some patients.
Study: 9021434
Drug: Racemic ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Racemic ibuprofen (400 mg)
Study: 8206111
Drug: Pyridostigmine, 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine, 120 mg p.o.
Study: 8206111
Drug: Pyridostigmine, 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine, 120 mg p.o. (GHRH stimulated)
Study: 3382764
Drug: Tamoxifen at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen at a dose of 10 mg twice daily
Study: 30467695
Drug: Niaoduqing Particles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niaoduqing Particles (5 g thrice daily and 10 g before bedtime for 24 weeks)
Study: 30467695
Drug: Niaoduqing Particles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niaoduqing Particles (after open-label treatment)
Study: 28460246
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment (COPE)
Study: 25857594
Drug: Tratinterol hydrochloride
Normalized name: Chlorpromazine Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tratinterol hydrochloride tablets
Study: 25857594
Drug: Procaterol hydrochloride
Normalized name: procaterol hydrochloride
DrugBank: Procaterol (DB01366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procaterol hydrochloride tablets (control)
Study: 21649522
Drug: Bepotastine besilate
Normalized name: Bepotastine besilate
DrugBank: Bepotastine (DB04890)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bepotastine besilate ophthalmic solution 1.5%
Study: 21649522
Drug: Bepotastine besilate
Normalized name: Bepotastine besilate
DrugBank: Bepotastine (DB04890)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bepotastine besilate ophthalmic solution 1.0%
Study: 7812991
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg oral clomipramine daily
Study: 7812991
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg oral clomipramine daily
Study: 65126
Drug: Immune serum
Normalized name: IMMUNE SERUMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune serum globulin (20 ml)
Study: 31567325
Drug: Intrathecal Drug
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal Drug Delivery Systems (IDDS)
Study: 23234632
Drug: Denosumab (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (180 mg subcutaneous every 4 weeks)
Study: 23234632
Drug: Denosumab (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (180 mg subcutaneous every 12 weeks)
Study: 15539971
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitors and beta blockers
Study: 15539971
Drug: Aldosterone blocking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldosterone blocking agents
Study: 9646192
Drug: Colloidal bismuth
Normalized name: Colloidal bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal bismuth subcitrate 240 mg twice daily
Study: 9646192
Drug: Colloidal bismuth
Normalized name: Colloidal bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal bismuth subcitrate 120 mg nightly
Study: 9646192
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg nightly
Study: 3612896
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (10 g as SuperCharR suspension) administered 2 hr prior, and at 0, 2, 6, and 8 hr after tobramycin administration.
Study: 3612896
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no activated charcoal treatment).
Study: 23213069
Drug: belimumab 10
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: belimumab 10 mg/kg
Study: 28685495
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg rosuvastatin combined with 10 mg metformin (T1)
Study: 28685495
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg rosuvastatin combined with 50 mg metformin (T2)
Study: 28685495
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg rosuvastatin combined with 500 mg metformin (T3)
Study: 28685495
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg rosuvastatin combined with 1 mg furosemide (T4)
Study: 28685495
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg rosuvastatin combined with 5 mg furosemide (T5)
Study: 27782861
Drug: Acupuncture (eight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (eight pragmatic Traditional Chinese Medicine treatments over 4 weeks)
Study: 10199862
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (50 microgram/day)
Study: 12870680
Drug: Directly Observed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directly Observed Therapy (DOT)
Study: 25624387
Drug: 0.2‐0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2‐0.5 mg/kg oral morphine
Study: 25624387
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg of oral ibuprofen
Study: 21677052
Drug: High fructose
Normalized name: High Fructose Corn Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fructose (HF) - 80 g fructose/d
Study: 21677052
Drug: High sucrose
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High sucrose (HS) - 80 g sucrose/d
Study: 21677052
Drug: Medium fructose
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medium fructose (MF) - 40 g fructose/d
Study: 21677052
Drug: Medium glucose
Normalized name: Medium glucose concentration peritoneal dialysis solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium glucose (MG) - 40 g glucose/d
Study: 21677052
Drug: High glucose
Normalized name: ONE TOUCH HIGH GLUCOSE CONTROL SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: High glucose (HG) - 80 g glucose/d
Study: 19434759
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment of bronchial arterial infusion (BAI) and rAd‐p53
Study: 14747675
Drug: H(2)-reduced (58)Fe
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: H(2)-reduced (58)Fe with 3 mg/100 g in tortillas
Study: 14747675
Drug: H(2)-reduced (58)Fe
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: H(2)-reduced (58)Fe with 3 mg/100 g in tortillas plus Na(2)EDTA at a ratio of 1:2 mol/mol
Study: 10966700
Drug: 1.5 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mL/kg
Study: 10966700
Drug: 2.0 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mL/kg
Study: 10966700
Drug: 2.5 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mL/kg
Study: 10966700
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose of 100 mL
Study: 6370975
Drug: Nomifensine (100‐200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nomifensine (100‐200 mg/day)
Study: 11090260
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no supplements)
Study: 23216674
Drug: IFNβ‐1a, 44
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNβ‐1a, 44 μg subcutaneously three times weekly (tiw)
Study: 23216674
Drug: IFNβ‐1b, 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNβ‐1b, 250 μg subcutaneously every other day
Study: 18070305
Drug: Tilt training
Normalized name: TILT-123
DrugBank: TILT-123 (DB17519)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilt training (daily sessions for three months)
Study: 16250265
Drug: Fluvastatin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin therapy for 12 weeks
Study: 12020980
Drug: Lipid-lowering fibrate
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering fibrate (gemfibrozil 600 mg orally twice daily for 3 months, then combined with HRT for 6 months)
Study: 12020980
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (2 mg oestradiol + 1 mg norethisterone acetate once daily for 3 months, then combined with gemfibrozil for 6 months)
Study: 8998395
Drug: Mirtazapine 20
Normalized name: Mirtazapine 20 mg in 1 g TOPICAL OINTMENT [Mirataz]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine 20 mg/day (titrated up to 60 mg/day)
Study: 8998395
Drug: Doxepin 75
Normalized name: doxepin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxepin 75 mg/day (titrated up to 300 mg/day)
Study: 31451252
Drug: Nutrition Intervention
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition Intervention (NI) - EPA-enriched nutrition supplement (2 bottles/day, 550 kcal/day) during NACRT
Study: 30379936
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose pioglitazone (15 mg/day)
Study: 30379936
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose pioglitazone (7.5 mg/day)
Study: 24182347
Drug: sPD-1 concentrations
Normalized name: 5'-cEtG-sp-cEt5MeU-sp-cEt5MeU-sp-dT-sp-dA-sp-dT-sp-dT-spdA-sp-dT-sp-dA-sp-dG-sp-dG-sp-dG-sp-cEt5MeC-sp-cEt5MeU-sp-cEt5MeU-3'
Approvals — FDA: no, EMA: no, PMDA: no
Description: sPD-1 concentrations in early RA (median 0.421 ng/mL, IQR 0.04-2.560 ng/mL)
Study: 20560112
Drug: Immulina® (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immulina® (400 mg/day) for seven days
Study: 20560112
Drug: Immulina® (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immulina® (200 mg/day) for seven days
Study: 20560112
Drug: Immulina® (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immulina® (200 mg and 400 mg per day) for seven days
Study: 10470387
Drug: Group P50:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group P50: propofol 1% 10 ml/thiopentone 2.5% 10 ml
Study: 10470387
Drug: Group P75:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group P75: propofol 1% 15 ml/thiopentone 2.5% 5 ml
Study: 9156906
Drug: Dexamethasone (optimal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (optimal dose)
Study: 1862227
Drug: Combined regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined regimen of intramniotic prostaglandin (PG) F2a injection and intracervical laminaria tents (group A, 50 women)
Study: 1862227
Drug: Intramniotic PGF2a
Normalized name: PGF2A THAM
DrugBank: Dinoprost tromethamine (DB01160)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramniotic PGF2a injection only (group B, 51 women)
Study: 1862227
Drug: Laminaria tents
Normalized name: Laminaria digitata preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laminaria tents followed by intracervical PGF2a tablets insertion (group C, 27 women)
Study: 6134547
Drug: Intramuscular papaveretum
Normalized name: papaveretum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular papaveretum
Study: 21859051
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg melatonin nightly for 30 days
Study: 19008077
Drug: Valacyclovir 1
Normalized name: valacyclovir 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir 1 g twice daily (n=24)
Study: 11248761
Drug: Amlodipine (5mg/daily)
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine (5mg/daily)
Study: 11248761
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS (30mg/daily)
Study: 30206690
Drug: Remifentanil (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (0.5 µg/kg/min)
Study: 23418465
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of ADVAX (DNA vaccine) + 2 doses of TBC-M4 (recombinant MVA) in Group A
Study: 23418465
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of TBC-M4 (recombinant MVA) in Group B
Study: 12117879
Drug: Folate supplementation
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folate supplementation (2 mg folic acid per day for three months)